NASDAQ: ATHE - Alterity Therapeutics Limited

Yield per half year: +175%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Alterity Therapeutics Limited

Extended chart Simple chart
Financial Markets by TradingView

About Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

more details
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2002-09-05
ISIN US02155X1063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://alteritytherapeutics.com
Цена ао 3.56
Change price per day: 0% (3.3)
Change price per week: +19.78% (2.755)
Change price per month: -18.11% (4.03)
Change price per 3 month: -0.3924% (3.313)
Change price per half year: +175% (1.2)
Change price per year: +54.21% (2.14)
Change price per 3 year: +306% (0.8128)
Change price per 5 year: +436.67% (0.6149)
Change price per year to date: +50% (2.2)
All parameters

Underestimation

Title Value Grade
P/S 2454.6 1
P/BV 715.01 1
P/E 0 0
EV/EBITDA -503.45 0
Total: 0.625

Efficiency

Title Value Grade
ROA, % -82.18 0
ROE, % -104.47 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0081 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 876.58 10
Yield Ebitda, % 89.99 9
Yield EPS, % -48.11 0
Total: 6.6
More

Institutions Volume Share, %
Morgan Stanley 51485 0.7
Bank of Montreal/Can/ 14907 0.2
Twin Lakes Capital Management, LLC 5925 0.08
Providence Capital Advisors, LLC 200 0
Coppell Advisory Solutions, LLC 149 0
Osaic Holdings Inc 81 0
Sugarloaf Wealth Management, LLC 33 0
Steward Partners Investment Advisory, LLC 6 0



Head Job title Payment Year of birth
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (70 years)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (64 years)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (66 years)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (66 years)
Dr. Steven D. Targum M.D. Chief Medical Advisor

Address: Australia, Melbourne, 350 Collins Street - open in Google maps, open in Yandex maps
Website: https://alteritytherapeutics.com